First Tracks Biotherapeutics
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
2DecExpected
Q2 2026
Next
-0.82
-0.78
-0.74
-0.7
Expected EPS
-0.80253016662
Actual EPS
N/A
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Show more...
CEO
Daniel R. Faga
Employees
104
Country
United States
ISIN
US3371851029
Listings
0 Comments
Share your thoughts
FAQ
What is First Tracks Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange First Tracks Biotherapeutics stocks are traded under the ticker B43.MU.
When is the next First Tracks Biotherapeutics earnings date?▼
First Tracks Biotherapeutics is going to release the next earnings report on December 02, 2026.
What were First Tracks Biotherapeutics earnings last quarter?▼
B43.MU earnings for the last quarter are -0.82 EUR per share, whereas the estimation was -0.7 EUR resulting in a -18.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does First Tracks Biotherapeutics have?▼
As of September 26, 2026, the company has 104 employees.
In which sector is First Tracks Biotherapeutics located?▼
First Tracks Biotherapeutics operates in the Health & Wellness sector.
When did First Tracks Biotherapeutics complete a stock split?▼
First Tracks Biotherapeutics has not had any recent stock splits.
Where is First Tracks Biotherapeutics headquartered?▼
First Tracks Biotherapeutics is headquartered in SAN DIEGO, United States.